0000000000156205

AUTHOR

Sattar N

showing 2 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology a…

2016

ABI : ankle–brachial (blood pressure) index ABPM : ambulatory blood pressure monitoring ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin-converting enzyme inhibitor ACS : acute coronary syndromes ADVANCE : Action in Diabetes and Vascular disease: PreterAx

Cost-Benefit AnalysisGeneral Practice030204 cardiovascular system & hematologyGuidelineDiabete0302 clinical medicineHyperlipidemiaStakeholderMedicine030212 general & internal medicineMultiple Chronic ConditionsPractice Patterns Physicians'Societies MedicalRisk assessmenteducation.field_of_studyCardiac RehabilitationDiabetesRehabilitationSmokingPsychosocial factorAge FactorsLipidMiddle AgedPrimary carePedigreeEuropeCardiovascular DiseasesPsychosocial factorsHypertensionBlood pressureDiet HealthyRisk assessmentCardiology and Cardiovascular MedicineAdultDiagnostic Imagingmedicine.medical_specialtyAmbulatory blood pressurePopulationPopulationCardiologyHealthy lifestyleHyperlipidemiasHealth PromotionDiabetic angiopathyGuidelinesRisk Assessment03 medical and health sciencesSex FactorsDiabetes mellitusJournal ArticleHumansClinical settingsHealthy LifestyleIntensive care medicineeducationExerciseAntihypertensive AgentsNutritionAgedbusiness.industryVascular diseasePhysical activityPreventionmedicine.diseasebody regionsClinical settingBlood pressureRisk managementSocioeconomic FactorsSmoking CessationJoint Esc GuidelinesbusinessBiomarkersDiabetic Angiopathies
researchProduct